Abstract:Background Schisanlactone E, also known as XueTongSu (XTS), is an active compound extracted from the traditional Tujia medicine Kadsura heteroclita ("XueTong"). Recent studies highlight its anti-inflammatory and antioxidant properties, yet the mechanisms of XTS's therapeutic effects on Alzheimer's disease (AD) are unclear. This study aims to elucidate the therapeutic efficacy and mechanisms of XTS in AD.Methods Ten C57BL/6 mice were assigned to the control group (NC), and twenty APP/PS1 transgenic mice were randomly divided into the model group (M) (10 mice) and the XTS treatment group (Tre) (10 mice). After an acclimatization period of 7 days, intraperitoneal injections were administered over a 60-day treatment period. The NC and M groups received saline, while the Tre group received XTS at 2 mg/kg. Learning and memory abilities were assessed using the Morris Water Maze (MWM) test. Histopathological changes were evaluated using hematoxylin and eosin (HE) and Nissl staining, and immunofluorescence was used to assess pathological products and glial cell activation. Cytokine levels (IL-1 beta, IL-6, TNF-alpha) in the hippocampus were quantified by qPCR. 16S rDNA sequencing analyzed gut microbiota metabolic alterations, and metabolomic analysis was performed on cortical samples. The KEGG database was used to analyze the regulatory mechanisms of XTS in AD treatment.Results XTS significantly improved learning and spatial memory in APP/PS1 mice and ameliorated histopathological changes, reducing A beta plaque aggregation and glial cell activation. XTS decreased the expression of inflammatory cytokines IL-1 beta, IL-6, and TNF-alpha. It also enhanced gut microbiota diversity, notably increasing Akkermansia species, and modulated levels of metabolites such as isosakuranetin, 5-KETE, 4-methylcatechol, and sphinganine. Pathway analysis indicated that XTS regulated carbohydrate metabolism, neuroactive ligand-receptor interactions, and alanine, aspartate, and glutamate metabolism, mitigating gut microbiota dysbiosis and metabolic disturbances.Conclusion XTS ameliorates cognitive deficits, pathological changes, and inflammatory responses in APP/PS1 mice. It significantly modulates the gut microbiota, particularly increasing Akkermansia abundance, and influences levels of key metabolites in both the gut and brain. These findings suggest that XTS exerts anti-AD effects through the microbial-gut-brain axis (MGBA).

TESC overexpression mitigates amyloid-β-induced hippocampal atrophy and memory decline

The protective effects of Esculentoside A through AMPK in the triple transgenic mouse model of Alzheimer's disease

Enhanced hippocampal TIAM2S expression alleviates cognitive deficits in Alzheimer's disease model mice

Tetrahydroxy stilbene glycoside (TSG) antagonizes Aβ-induced hippocampal neuron injury by suppressing mitochondrial dysfunction via Nrf2-dependent HO-1 pathway.

Hippocampal transcriptome-wide association study and neurobiological pathway analysis for Alzheimer’s disease

Overexpression of TECPR1 improved cognitive function of P301S‐tau mice via activation of autophagy in the early and late process

Hippocampal Transcriptome-Wide Association Study and Neurobiological Pathway Analysis for Alzheimer's Disease.

Long-term gamma transcranial alternating current stimulation improves the memory function of mice with Alzheimer's disease

Tetrahydroxy stilbene glycoside regulates TGF-β/fractalkine/CX3CR1 based on network pharmacology in APP/PS1 mouse model

Stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau in cellular and mouse models of tauopathies

TFEB Enhances Astroglial Uptake of Extracellular Tau Species and Reduces Tau Spreading.

Long-term Gamma Transcranial Alternating Current Stimulation Improves the Memory Function of Mice with Alzheimer’s Disease

Exploring the multifaceted therapeutic mechanism of Schisanlactone E (XTS) in APP/PS1 mouse model of Alzheimer's disease through multi-omics analysis

Modulation of Long-Term Potentiation by Gamma Frequency Transcranial Alternating Current Stimulation in Transgenic Mouse Models of Alzheimer’s Disease

Targeting a Vulnerable Septum-Hippocampus Cholinergic Circuit in a Critical Time Window Ameliorates Tau-Impaired Memory Consolidation.

Tau activation of microglial cGAS–IFN reduces MEF2C-mediated cognitive resilience

Taohong siwu decoction ameliorates cognitive dysfunction through SIRT6/ER stress pathway in Alzheimer's disease

Escitalopram Alleviates Alzheimer's Disease-Type Tau Pathologies in the Aged P301L Tau Transgenic Mice.

Tuberous sclerosis complex-1 (TSC1) contributes to selective neuronal vulnerability in Alzheimer's disease

Genome-Wide Association and Interaction Study on Quantitative Traits of CSF Phosphorylated Tau in ADNI Cohort.

Exploring the Multifaceted Therapeutic Mechanism of Schisanlactone E (XTS) in APP/PS1 Mouse Model of Alzheimer’s Disease Through Multi-Omics Analysis